STUDY OBJECTIVES: Obstructive sleep apnea (OSA) and type 2 diabetes mellitus (T2DM) are prevalent disorders that pose increased risk of cardiovascular disease and death. The objective of this study was to clarify if continuous positive airway pressure (CPAP) therapy for OSA affects T2DM control and emergence. METHODS: Point-of-care, comparative effectiveness study; cross-sectional and longitudinal analyses. RESULTS: Our cohort included 928 consecutive patients; 13% were women; 36% were Caucasians and 61% African-Americans. OSA was diagnosed in approximately 738 patients and CPAP was initiated in 718 patients; median duration of therapy was 5 mo (25% to 75% interquartile range [IQR] 3-14). Patients with OSA used CPAP therapy for a median duration of 4.8 h, 34.5% of the nights. Adherence to CPAP was prespecified as follows: good (≥ 70% nights and ≥ 4 h/night), excellent (≥ 80% nights and ≥ 6 h/night) or outstanding (≥ 90% of nights and 8 h/night). Based on objective data, good, excellent, and outstanding compliance were found in only 30%, 20%, and 6%, respectively. Three percent of subjects without CPAP follow-up and less than 4% of those nonadherent to CPAP therapy (based on the established criteria) developed incident T2DM. Incident T2DM developed in only 0.8% of those with good compliance and in none (0%) of those in the excellent and outstanding groups. During follow-up, median weight change was +0.3 kg (IQR -1.8 to 2.7). CONCLUSIONS: We found that an outstanding compliance to CPAP reduced fasting blood glucose in patients with OSA. Longitudinally, higher levels of therapeutic adherence may affect the rate of incident impaired fasting glucose, prediabetes, and T2DM, despite the observed weight gains. COMMENTARY: A commentary on this article appears in this issue on page 365.
STUDY OBJECTIVES:Obstructive sleep apnea (OSA) and type 2 diabetes mellitus (T2DM) are prevalent disorders that pose increased risk of cardiovascular disease and death. The objective of this study was to clarify if continuous positive airway pressure (CPAP) therapy for OSA affects T2DM control and emergence. METHODS: Point-of-care, comparative effectiveness study; cross-sectional and longitudinal analyses. RESULTS: Our cohort included 928 consecutive patients; 13% were women; 36% were Caucasians and 61% African-Americans. OSA was diagnosed in approximately 738 patients and CPAP was initiated in 718 patients; median duration of therapy was 5 mo (25% to 75% interquartile range [IQR] 3-14). Patients with OSA used CPAP therapy for a median duration of 4.8 h, 34.5% of the nights. Adherence to CPAP was prespecified as follows: good (≥ 70% nights and ≥ 4 h/night), excellent (≥ 80% nights and ≥ 6 h/night) or outstanding (≥ 90% of nights and 8 h/night). Based on objective data, good, excellent, and outstanding compliance were found in only 30%, 20%, and 6%, respectively. Three percent of subjects without CPAP follow-up and less than 4% of those nonadherent to CPAP therapy (based on the established criteria) developed incident T2DM. Incident T2DM developed in only 0.8% of those with good compliance and in none (0%) of those in the excellent and outstanding groups. During follow-up, median weight change was +0.3 kg (IQR -1.8 to 2.7). CONCLUSIONS: We found that an outstanding compliance to CPAP reduced fasting blood glucose in patients with OSA. Longitudinally, higher levels of therapeutic adherence may affect the rate of incident impaired fasting glucose, prediabetes, and T2DM, despite the observed weight gains. COMMENTARY: A commentary on this article appears in this issue on page 365.
Authors: Amy M Sawyer; Nalaka S Gooneratne; Carole L Marcus; Dafna Ofer; Kathy C Richards; Terri E Weaver Journal: Sleep Med Rev Date: 2011-06-08 Impact factor: 11.609
Authors: Jonathan E Shaw; Naresh M Punjabi; Matthew T Naughton; Leslee Willes; Richard M Bergenstal; Peter A Cistulli; Greg R Fulcher; Glenn N Richards; Paul Z Zimmet Journal: Am J Respir Crit Care Med Date: 2016-08-15 Impact factor: 21.405
Authors: Paul C Myhill; Wendy A Davis; Kirsten E Peters; S A Paul Chubb; David Hillman; Timothy M E Davis Journal: J Clin Endocrinol Metab Date: 2012-09-07 Impact factor: 5.958
Authors: Igor Alexander Harsch; Simin Pour Schahin; Kerstin Brückner; Martin Radespiel-Tröger; Florian S Fuchs; Eckhart Georg Hahn; Peter Christopher Konturek; Tobias Lohmann; Joachim Hans Ficker Journal: Respiration Date: 2004 May-Jun Impact factor: 3.580
Authors: Arthur Dawson; Susan L Abel; Richard T Loving; George Dailey; Farhad F Shadan; John W Cronin; Daniel F Kripke; Lawrence E Kline Journal: J Clin Sleep Med Date: 2008-12-15 Impact factor: 4.062
Authors: Brian D Kent; Ludger Grote; Silke Ryan; Jean-Louis Pépin; Maria R Bonsignore; Ruzena Tkacova; Tarja Saaresranta; Johan Verbraecken; Patrick Lévy; Jan Hedner; Walter T McNicholas Journal: Chest Date: 2014-10 Impact factor: 9.410
Authors: Susheel P Patil; Indu A Ayappa; Sean M Caples; R Joh Kimoff; Sanjay R Patel; Christopher G Harrod Journal: J Clin Sleep Med Date: 2019-02-15 Impact factor: 4.062
Authors: Lucas M Donovan; Michael Rueschman; Jia Weng; Nisha Basu; Katherine A Dudley; Jessie P Bakker; Rui Wang; Suzanne M Bertisch; Sanjay R Patel Journal: Diabetes Res Clin Pract Date: 2017-10-18 Impact factor: 5.602
Authors: David F Smith; Kathleen M Sarber; Charlene P Spiceland; Stacey L Ishman; Dianne M Augelli; Ann M Romaker Journal: J Clin Sleep Med Date: 2019-07-15 Impact factor: 4.062
Authors: James Patrick Smith; Luke G Cyr; Laura K Dowd; Kyla S Duchin; Priscilla A Lenihan; Jennifer Sprague Journal: Optom Vis Sci Date: 2019-11 Impact factor: 1.973